Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

[1]  J. W. Flesher,et al.  Phosphonic Acid Analogs of Nucleoside Phosphates. I. The Synthesis of 5″-Adenylyl Methylenediphosphonate, a Phosphonic Acid Analog of ATP , 1963 .

[2]  V. Dixit,et al.  RIP2 Is a Novel NF-κB-activating and Cell Death-inducing Kinase* , 1998, The Journal of Biological Chemistry.

[3]  L. del Peso,et al.  RICK, a Novel Protein Kinase Containing a Caspase Recruitment Domain, Interacts with CLARP and Regulates CD95-mediated Apoptosis* , 1998, The Journal of Biological Chemistry.

[4]  J. Bertin,et al.  Human CARD4 Protein Is a Novel CED-4/Apaf-1 Cell Death Family Member That Activates NF-κB* , 1999, The Journal of Biological Chemistry.

[5]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[6]  Oleksandr V. Buzko,et al.  A kinase sequence database: sequence alignments and family assignment , 2002, Bioinform..

[7]  C. O'Morain,et al.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. , 2002, American journal of human genetics.

[8]  M. Chamaillard,et al.  Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection* , 2003, The Journal of Biological Chemistry.

[9]  J. Bertin,et al.  Nod1 Detects a Unique Muropeptide from Gram-Negative Bacterial Peptidoglycan , 2003, Science.

[10]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[11]  G. Argast,et al.  Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK , 2005, Molecular and Cellular Biochemistry.

[12]  W. Cookson,et al.  NOD1 variation, immunoglobulin E and asthma. , 2005, Human molecular genetics.

[13]  D. Jewell,et al.  Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. , 2005, Human molecular genetics.

[14]  Chafen Lu,et al.  Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. , 2006, Cellular signalling.

[15]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[16]  Y. Eishi,et al.  Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. , 2006, Biochimica et biophysica acta.

[17]  J. Hugot,et al.  The NOD2-RICK Complex Signals from the Plasma Membrane* , 2007, Journal of Biological Chemistry.

[18]  P. Cohen,et al.  Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. , 2007, The Biochemical journal.

[19]  P. Lucas,et al.  A critical role of RICK/RIP2 polyubiquitination in Nod‐induced NF‐κB activation , 2008 .

[20]  V. Annese,et al.  Mucosal NOD2 expression and NF‐&kgr;B activation in pediatric Crohn's disease , 2008, Inflammatory bowel diseases.

[21]  Baoguang Zhao,et al.  Design, synthesis and selection of DNA-encoded small-molecule libraries. , 2009, Nature chemical biology.

[22]  L. Stronati,et al.  Activation of NOD2‐mediated intestinal pathway in a pediatric population with Crohn's disease , 2009, Inflammatory bowel diseases.

[23]  D. Philpott,et al.  Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry , 2010, Nature Immunology.

[24]  J. Asara,et al.  Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses. , 2010, Genes & development.

[25]  L. Stronati,et al.  Altered expression of innate immunity genes in different intestinal sites of children with ulcerative colitis. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[27]  C. Wouters,et al.  Blau syndrome revisited , 2011, Current opinion in rheumatology.

[28]  Joseph L. Kim,et al.  Conformation-specific effects of Raf kinase inhibitors. , 2012, Journal of medicinal chemistry.

[29]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.

[30]  J. Bertin,et al.  Identification of Benzimidazole Diamides as Selective Inhibitors of the Nucleotide-Binding Oligomerization Domain 2 (NOD2) Signaling Pathway , 2013, PloS one.

[31]  L. Mahan,et al.  Correction to “The Kinetics of Competitive Radioligand Binding Predicted by the Law of Mass Action” , 2014, Molecular Pharmacology.

[32]  D. Philpott,et al.  NOD proteins: regulators of inflammation in health and disease , 2013, Nature Reviews Immunology.

[33]  J. Bertin,et al.  Identification of Selective Small Molecule Inhibitors of the Nucleotide-Binding Oligomerization Domain 1 (NOD1) Signaling Pathway , 2014, PloS one.

[34]  Eiki Sekine,et al.  Engagement of Nucleotide-binding Oligomerization Domain-containing Protein 1 (NOD1) by Receptor-interacting Protein 2 (RIP2) Is Insufficient for Signal Transduction , 2014, The Journal of Biological Chemistry.

[35]  S. Knapp,et al.  Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.

[36]  J. Sandow,et al.  A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production , 2015, Nature Communications.